Hanassab Simon, Abbara Ali, Yeung Arthur C, Voliotis Margaritis, Tsaneva-Atanasova Krasimira, Kelsey Tom W, Trew Geoffrey H, Nelson Scott M, Heinis Thomas, Dhillo Waljit S
Department of Metabolism, Digestion, and Reproduction, Imperial College London, London, UK.
Department of Computing, Imperial College London, London, UK.
NPJ Digit Med. 2024 Mar 1;7(1):55. doi: 10.1038/s41746-024-01006-x.
Infertility affects 1-in-6 couples, with repeated intensive cycles of assisted reproductive technology (ART) required by many to achieve a desired live birth. In ART, typically, clinicians and laboratory staff consider patient characteristics, previous treatment responses, and ongoing monitoring to determine treatment decisions. However, the reproducibility, weighting, and interpretation of these characteristics are contentious, and highly operator-dependent, resulting in considerable reliance on clinical experience. Artificial intelligence (AI) is ideally suited to handle, process, and analyze large, dynamic, temporal datasets with multiple intermediary outcomes that are generated during an ART cycle. Here, we review how AI has demonstrated potential for optimization and personalization of key steps in a reproducible manner, including: drug selection and dosing, cycle monitoring, induction of oocyte maturation, and selection of the most competent gametes and embryos, to improve the overall efficacy and safety of ART.
不孕不育影响着六分之一的夫妇,许多人需要反复进行强化的辅助生殖技术(ART)周期才能实现理想的活产。在ART中,临床医生和实验室工作人员通常会考虑患者特征、既往治疗反应以及持续监测情况来做出治疗决策。然而,这些特征的可重复性、权重和解读存在争议,且高度依赖操作人员,导致很大程度上依赖临床经验。人工智能(AI)非常适合处理、加工和分析ART周期中产生的具有多个中间结果的大型、动态、时间性数据集。在此,我们回顾了AI如何以可重复的方式展现出优化和个性化关键步骤的潜力,这些步骤包括:药物选择和剂量确定、周期监测、卵母细胞成熟诱导以及选择最具活力的配子和胚胎,以提高ART的整体疗效和安全性。